Page last updated: 2024-10-27

fluorouracil and Headache

fluorouracil has been researched along with Headache in 10 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Headache: The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.

Research Excerpts

ExcerptRelevanceReference
" A sample of 43 patients with breast cancer was accrued from September to November 1992 in a phase II study to assess the efficacy of granisetron in patients receiving FEC (5-FU, epirubicin, cyclophosphamide)."9.07Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide. ( Ang, PT; Khoo, KS; Tan, EH, 1994)
" She was under treatment by fluorouracil, leucovorin, oxaliplatin, and docetaxel regimen and thrombocytopenia regimen after tumor progression, but developed unconsciousness, irritability, and headache shortly after initiation of treatment."8.31Posterior reversible encephalopathy syndrome triggered by FLOT (5-fluorouracil, oxaliplatin, docetaxel, and calcium levofolinate) chemotherapy and thrombocytopenia (docetaxel and cisplatin) chemotherapy. ( Xie, L, 2023)
"For over 50 years, 5-Fluorouracil has played a critical role in the treatment of numerous malignancies, including colorectal cancer."7.96Optic neuritis induced by 5-fluorouracil chemotherapy: Case report and review of the literature. ( Gilbar, PJ; Grewal, GD; Holcombe, DJ; Raina, AJ, 2020)
"Headaches have been reported as a potential side effect of capecitabine therapy."7.74Capecitabine-induced headache responding to diltiazem. ( Fakih, MG; Raman, AK, 2007)
" Patients exhibited high compliance in dosing administration."6.74Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy. ( Akhmadullina, LI; Barker, NP; Davidenko, IS; Firsov, I; Gertner, JM; Gotovkin, EA; Kopp, MV; Kulikov, EP; Moiseyenko, VM; Peterson, DE; Rakovskaya, GN; Rodionova, I; Sherman, NZ; Shinkarev, SA; Tuleneva, T; Woon, CW; Yarosh, A, 2009)
" A sample of 43 patients with breast cancer was accrued from September to November 1992 in a phase II study to assess the efficacy of granisetron in patients receiving FEC (5-FU, epirubicin, cyclophosphamide)."5.07Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide. ( Ang, PT; Khoo, KS; Tan, EH, 1994)
" She was under treatment by fluorouracil, leucovorin, oxaliplatin, and docetaxel regimen and thrombocytopenia regimen after tumor progression, but developed unconsciousness, irritability, and headache shortly after initiation of treatment."4.31Posterior reversible encephalopathy syndrome triggered by FLOT (5-fluorouracil, oxaliplatin, docetaxel, and calcium levofolinate) chemotherapy and thrombocytopenia (docetaxel and cisplatin) chemotherapy. ( Xie, L, 2023)
"For over 50 years, 5-Fluorouracil has played a critical role in the treatment of numerous malignancies, including colorectal cancer."3.96Optic neuritis induced by 5-fluorouracil chemotherapy: Case report and review of the literature. ( Gilbar, PJ; Grewal, GD; Holcombe, DJ; Raina, AJ, 2020)
"Headaches have been reported as a potential side effect of capecitabine therapy."3.74Capecitabine-induced headache responding to diltiazem. ( Fakih, MG; Raman, AK, 2007)
"7% of patients experienced grade 3 and 4 adverse events, respectively."2.80Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. ( Campone, M; Citron, ML; Dang, CT; Dirix, L; Gianni, L; Krop, IE; Romieu, G; Smitt, M; Suter, TM; Xu, N; Zamagni, C, 2015)
" Patients exhibited high compliance in dosing administration."2.74Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy. ( Akhmadullina, LI; Barker, NP; Davidenko, IS; Firsov, I; Gertner, JM; Gotovkin, EA; Kopp, MV; Kulikov, EP; Moiseyenko, VM; Peterson, DE; Rakovskaya, GN; Rodionova, I; Sherman, NZ; Shinkarev, SA; Tuleneva, T; Woon, CW; Yarosh, A, 2009)

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (40.00)18.2507
2000's2 (20.00)29.6817
2010's2 (20.00)24.3611
2020's2 (20.00)2.80

Authors

AuthorsStudies
Xie, L1
Raina, AJ1
Gilbar, PJ1
Grewal, GD1
Holcombe, DJ1
Nguyen, MT1
Stoianovici, R1
Brunetti, L1
Krop, IE1
Suter, TM1
Dang, CT1
Dirix, L1
Romieu, G1
Zamagni, C1
Citron, ML1
Campone, M1
Xu, N1
Smitt, M1
Gianni, L1
Peterson, DE1
Barker, NP1
Akhmadullina, LI1
Rodionova, I1
Sherman, NZ1
Davidenko, IS1
Rakovskaya, GN1
Gotovkin, EA1
Shinkarev, SA1
Kopp, MV1
Kulikov, EP1
Moiseyenko, VM1
Gertner, JM1
Firsov, I1
Tuleneva, T1
Yarosh, A1
Woon, CW1
Raman, AK1
Fakih, MG1
Köhne, CH1
Hiddemann, W1
Schüller, J1
Weiss, J1
Lohrmann, HP1
Schmitz-Hübner, U1
Bodenstein, H1
Schöber, C1
Wilke, H1
Grem, J1
Tan, EH1
Ang, PT1
Khoo, KS1
Stuart, K1
Tessitore, J1
Huberman, M1
Noguerón, E1
Berrocal, A1
Albert, A1
Camps, C1
Vicent, JM1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multicenter, Multinational Phase II Study to Assess the Clinical Safety and Feasibility of Trastuzumab Emtansine Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage HER2-positive Breast Ca[NCT01196052]Phase 2153 participants (Actual)Interventional2010-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Percentage of Participants Who Completed ≥ 95% of the Planned Radiotherapy Treatment With Concurrent Trastuzumab Emtansine Administration Without Significant (> 5 Days) Delay

(NCT01196052)
Timeframe: From the start to the end of radiotherapy treatment (up to 51 weeks)

InterventionPercentage of participants (Number)
Trastuzumab Emtansine94.7

Percentage of Participants Who Completed the Planned Duration of Trastuzumab Emtansine Treatment

Participants were to receive up to a total of 17 cycles of trastuzumab emtansine. If trastuzumab was given concurrently with either the optional docetaxel or optional radiation, then the number of 3-week cycles of trastuzumab therapy was subtracted from the planned 17 cycles of trastuzumab emtansine therapy. (NCT01196052)
Timeframe: From the start to the end of trastuzumab emtansine treatment (up to 51 weeks)

InterventionPercentage of participants (Number)
Trastuzumab Emtansine82.4

Percentage of Participants Who Experienced at Least 1 Adverse Event During Concurrent Hormonal Therapy With Trastuzumab Emtansine Treatment

(NCT01196052)
Timeframe: From the start to the end of concurrent hormonal therapy (up to 51 weeks)

InterventionPercentage of participants (Number)
Trastuzumab Emtansine69.4

Percentage of Participants Who Experienced at Least 1 Adverse Event During Concurrent Radiotherapy With Trastuzumab Emtansine Treatment

(NCT01196052)
Timeframe: From the start to the end of concurrent radiotherapy (up to 51 weeks)

InterventionPercentage of participants (Number)
Trastuzumab Emtansine94.9

Percentage of Participants With a Cardiac Event Within 12 Weeks After the Start of Trastuzumab Emtansine Treatment

A cardiac event was defined as death from a cardiac cause or severe congestive failure (New York Heart Association [NYHA] Class III or IV) with a decrease in left ventricular ejection fraction (LVEF) of ≥ 10% from Baseline to an LVEF of < 50%. (NCT01196052)
Timeframe: Baseline to 12 weeks after the start of trastuzumab emtansine treatment

InterventionPercentage of participants (Number)
Trastuzumab Emtansine0

Percentage of Participants With a Pathological Complete Response

Pathological complete response was defined as the absence of invasive neoplastic cells at microscopic examination of the primary tumor and lymph nodes after surgery following primary systemic therapy. Pathological complete response was evaluated in participants treated with neoadjuvant therapy doxorubicin/cyclophosphamide-5-fluorouracil/epirubicin/cyclophosphamide followed by 1 or more doses of trastuzumab emtansine and who underwent surgery. (NCT01196052)
Timeframe: Day of surgery

InterventionPercentage of participants (Number)
Trastuzumab Emtansine56.0

Adverse Events, LVEF Function, and Deaths

The following percentages of participants are reported: At least 1 adverse event while receiving T-DM1; at least 1 serious adverse event while receiving T-DM1; an adverse event leading to discontinuation, dose delay, or dose reduction of trastuzumab emtansine treatment; symptomatic cardiac dysfunction; and asymptomatic decline in left ventricular ejection fraction (LVEF). An asymptomatic LVEF decline was defined as a LVEF < 50% and a maximum decrease ≥ 10% from Baseline. The percentage of participants who died is reported. (NCT01196052)
Timeframe: From the start to the end of trastuzumab emtansine treatment (up to 51 weeks)

InterventionPercentage of participants (Number)
At least 1 adverse event (AE)At least 1 serious adverse eventAn AE leading to treatment discontinuationAn AE leading to dose delayAn AE leading to dose reductionSymptomatic cardiac dysfunctionAn asymptomatic decline in LVEFDeaths
Trastuzumab Emtansine98.610.113.529.121.60.02.70

Trials

4 trials available for fluorouracil and Headache

ArticleYear
Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Apr-01, Volume: 33, Issue:10

    Topics: Adolescent; Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined

2015
Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-10, Volume: 27, Issue:26

    Topics: Abdominal Pain; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea

2009
Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:5

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla

1995
Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 1994, Volume: 2, Issue:3

    Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Constipation; Cyclophosphamide; Epirubicin; Fem

1994

Other Studies

6 other studies available for fluorouracil and Headache

ArticleYear
Posterior reversible encephalopathy syndrome triggered by FLOT (5-fluorouracil, oxaliplatin, docetaxel, and calcium levofolinate) chemotherapy and thrombocytopenia (docetaxel and cisplatin) chemotherapy.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2023, Volume: 29, Issue:6

    Topics: Calcium; Cisplatin; Docetaxel; Edema; Female; Fluorouracil; Headache; Humans; Leucovorin; Middle Age

2023
Optic neuritis induced by 5-fluorouracil chemotherapy: Case report and review of the literature.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020, Volume: 26, Issue:2

    Topics: Administration, Intravenous; Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Glucocortico

2020
Chemotherapy induced stroke mimic: 5-Fluorouracil encephalopathy fulfilling criteria for tissue plasminogen activator therapy.
    The American journal of emergency medicine, 2017, Volume: 35, Issue:9

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aphasia; Brain Dise

2017
Capecitabine-induced headache responding to diltiazem.
    Chemotherapy, 2007, Volume: 53, Issue:4

    Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diltiazem; Female; Fluorouracil

2007
5-Fluorouracil and alpha-interferon in hepatocellular carcinoma.
    American journal of clinical oncology, 1996, Volume: 19, Issue:2

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Ataxia; Carcinoma, Hepatocellular; Disease P

1996
[Acute cerebellar syndrome due to 5-fluorouracil].
    Revista de neurologia, 1997, Volume: 25, Issue:148

    Topics: Acute Disease; Antimetabolites, Antineoplastic; Cerebellar Ataxia; Fluorouracil; Headache; Humans; M

1997